Online inquiry

IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5172MR)

This product GTTS-WQ5172MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL13 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001354991.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596
UniProt ID P35225
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5172MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10835MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA M9346A
GTTS-WQ8354MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA hPAM4
GTTS-WQ2809MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG-301
GTTS-WQ13756MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN 1500
GTTS-WQ3009MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Angiocept
GTTS-WQ8576MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ2110MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ8271MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HM10560A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW